Abstract：
Acute chest syndrome (ACS) is a leading cause of morbimortality in sickle cell disease (SCD). In this prospective observational study, we investigated sputum interleukin-6 (IL-6) level as an ACS severity marker during 30 ACS episodes in 26 SCD children. Sputum IL-6 levels measured within the first 72 h of hospitalisation for ACS were significantly higher in patients with oxygen requirement ≥2 L/min, ventilation (invasive and/or non-invasive) length ≥5 days, bilateral and/or extensive opacities on chest X-ray or erythrocytapheresis requirement. Sputum IL-6 could serve as an ACS severity marker to help identify patients requiring targeted anti-inflammatory treatments such as tocilizumab.
摘要：
急性胸部综合征（ACS）是镰状细胞病（SCD）病态的主要原因。在这项前瞻性观察研究中，我们调查了26例SCD儿童在30例ACS发作期间痰中白细胞介素-6(IL-6)水平作为ACS严重程度标志物.在需氧量≥2L/min的患者中，ACS住院前72小时内测得的痰中IL-6水平明显较高。通气（有创和/或非有创）长度≥5天，胸部X线或红细胞分离术要求的双侧和/或广泛的混浊。痰IL-6可以作为ACS严重程度标志物，帮助识别需要靶向抗炎治疗如托珠单抗的患者。
